XNK Therapeutics AB, a Sweden-based clinical stage immunotherapy company that is focused on bringing new and more effective treatments to cancer patients, announced on Monday that Johan Liwing, CEO, will make a presentation at the DNB Nordic Healthcare Conference in Oslo, Norway, on 14 December at 10:15am CET.
This presentation will be followed by a short Q&A session, moderated by a DNB analyst.
The company is developing autologous NK cell-based cell therapy with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumour indications. Its most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration